AUTOSOMAL RECESSIVE POLYCYSTIC KIDNEY DISEASE (ARPKD)

Clinical trials for AUTOSOMAL RECESSIVE POLYCYSTIC KIDNEY DISEASE (ARPKD) explained in plain language.

Never miss a new study

Get alerted when new AUTOSOMAL RECESSIVE POLYCYSTIC KIDNEY DISEASE (ARPKD) trials appear

Sign up with your email to follow new studies for AUTOSOMAL RECESSIVE POLYCYSTIC KIDNEY DISEASE (ARPKD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

Hope for the youngest: drug trial aims to protect Babies' kidneys

Disease control Terminated

This study aimed to see if a drug called tolvaptan could help babies with a rare, serious genetic kidney disease (ARPKD) by delaying the need for dialysis or transplant. It planned to give the drug to infants under 12 weeks old for two years and track their kidney health. The tri…

Matched conditions: AUTOSOMAL RECESSIVE POLYCYSTIC KIDNEY DISEASE (ARPKD)

Phase: PHASE3 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control

Last updated Mar 09, 2026 14:26 UTC

AUTOSOMAL RECESSIVE POLYCYSTIC KIDNEY DISEASE (ARPKD)

Get alerted when new AUTOSOMAL RECESSIVE POLYCYSTIC KIDNEY DISEASE (ARPKD) trials appear

Hope for the youngest: drug trial aims to protect Babies' kidneys